Innovate UK £1.54m award for automated radiopharmaceutical production project

Medicines Discovery Catapult (MDC) and Astral Systems have secured £1.54m from Innovate UK to develop digital and automated laboratory processes for producing radiopharmaceuticals, with the aim of improving the speed, reliability and scalability of these increasingly important medicines.

Radiopharmaceuticals contain radioactive isotopes and are used in both diagnostic imaging and treatment, with growing potential in precision cancer care. More than 700,000 NHS procedures rely on these medicines each year, and demand is expected to increase as new radiopharmaceutical therapies progress through development.

Their manufacture presents particular challenges because the radioactive component decays over time and production and delivery must be coordinated to ensure medicines retain sufficient activity when they reach patients.

The project will combines MDC's expertise in radiopharmaceutical development with Astral Systems' engineering capabilities and compact multi-state fusion devices to create an integrated digital workflow. Current laboratory processes that involve separate systems, manual record-keeping and handovers between stages can increase the potential for errors and reducing efficiency.

The partners aim to connect these activities through automated processes and consistent data transfer, while incorporating virtual 'digital avatars'. These computer models will allow researchers to simulate and optimise processes before committing laboratory time and resources.

Copper-64 and copper-67, to be used as pilot radionuclides, have potential for both diagnostic imaging and targeted radiopharmaceutical therapy, providing an opportunity to demonstrate processes that could subsequently be adapted for other isotopes and laboratories.

Dr Mike Strange, CEO of Medicines Discovery Catapult, said the UK had world-class radiopharmaceutical science but needed the development and manufacturing capabilities to match it.

“This project is an important step towards ensuring the digital infrastructure is in place to support the next generation of radiopharmaceutical development in the UK and help bring new treatments closer to patients,” he said.

Talmon Firestone, CEO of Astral Systems, said the continuous decay of isotopes meant that every stage between the laboratory and patient mattered. The project would bring those stages together in an automated digital workflow, providing researchers with more reliable data and supporting future treatment development.

The funding comes through Innovate UK's Labs of the Future competition, part of the Transforming Medicines Manufacturing Innovation programme. Dr Hareklea Markides, innovation lead for medicines manufacturing at Innovate UK, said the project demonstrated the potential of digital-first production processes to improve resilience, access and productivity as demand for radiopharmaceuticals grows.

Related Content

Pin It on Pinterest

Share This